A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Clinical trial NCT04566770 · COMPLETED
Trial details
- NCT number
- NCT04566770
- Sponsor
- CanSino Biologics Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-24
- Primary completion
- 2021-09-21
- Enrollment
- 480
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.